2022 |
|---|
Aug 29, 2022
Brand Institute Partners on Brand Name Development for FDA Approved Hormonal Contraceptive Ring for the Prevention of Pregnancy Brand Institute is proud to announce its work with Mayne Pharma in developing the brand name HALOETTE®. |
|
Aug 23, 2022
Brand Institute to Moderate Round Table on Pharmaceutical Brand Naming Hosted by Harvard Business School Healthcare Alumni Association Brand Institute is pleased to announce that it will be moderating a Virtual Round Table (VRT) hosted by the Harvard Business School Healthcare Alumni Association (HBSHAA) titled: The Pursuit of a Global Pharmaceutical Brand Name. |
|
Aug 15, 2022
Brand Institute's Vice President of Market Research and Commercial Strategy on the Importance of Market Research Panels in Brand Development Brand Institute's Vice President of Market Research and Commercial Strategy, Joe Bazerghi, who spearheaded the expansion of Brand Institute's market research panel of health care providers and patients across 180 countries, offers sage advice on the importance of market research panels in naming and brand development. |
|
Aug 10, 2022
Brand Institute's Head of Trademarks on the Impact of the US Trademark Modernization Act of 2020 (TMA) Brand Institute's Head of Trademarks, Rogelio Reyes, Esq., is pleased to offer a summary regarding the Trademark Modernization Act of 2020 (TMA), which took effect on December 18, 2021. |
|
Aug 08, 2022
Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed. |
|
Aug 03, 2022
Brand Institute President of Nonproprietary Naming Division Advises Clients on Guidance Set Forth by INN Regarding COVID-19 Variant Vaccines Brand Institute's President of its Nonproprietary Naming Division, Sophia Fuerst, M.S., M.B.A., is pleased to offer summary insights regarding recently implemented procedures for international nonproprietary names (INNs), specifically INNs for Variant COVID-19 Vaccine Active Substances. |
|
Jul 27, 2022
Brand Institute's Jerry Phillips on the Impact of the FDA's Proposed Rule to Modify the NDC and Barcode Regulations Brand Institute (BI) is pleased to share President of Regulatory Strategy Jerry Phillips' summary on the recent FDA proposal to modify its regulations to establish a uniform, 12-digit format for the National Drug Code (NDC) (21 CFR 207.33) that can accommodate longer NDCs once the FDA begins issuing 6-digit labeler codes. |
|
Jul 25, 2022
Brand Institute Welcomes Former Amgen Associate General Counsel and Executive Director Timothy J. Gaul as Vice President of Intellectual Property Strategy Brand Institute is pleased to announce the appointment of Timothy J. Gaul to the role of Vice President, Intellectual Property Strategy. |
|
Jul 21, 2022
Brand Institute's President of Canadian Regulatory Affairs Updates Brand Name Assessment Methodology Based on Health Canada Trends Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is pleased to announce new processes in its workflow. |
|
Jul 05, 2022
Brand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan) Brand Institute is proud to announce its work with Solasia Pharma K.K. ("Solasia") in developing the brand name DARVIAS®. |
|
Jun 27, 2022
Brand Institute SVP of Nonproprietary Naming Division Shares Naming Guidance on Evolving Nomenclature Schemes Set Forth by Regulatory Agencies (USAN and INN) Brand Institute's Senior Vice President of Regulatory Affairs for the company's Nonproprietary Naming Division, Sandra Van Laan, B.S., is pleased to share new guidance on monoclonal antibody naming, published by INN in November 2021. |
|
Jun 27, 2022
Brand Institute Partners on Brand Name Development for European Commission Authorized Vaccine for the Prevention of Hepatitis B Brand Institute is proud to announce its work with VBI Vaccines in developing the brand name PreHevbri™. |
|
Jun 23, 2022
Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute Brand Institute, the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute. |
|
Jun 21, 2022
Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Febrile Neutropenia in Cancer Patients Brand Institute is proud to announce having worked with Adello Biologics (acquired by Kashiv Biosciences in 2019) in developing the brand name FYLNETRA® (pegfilgrastim-pbbk), for an injection used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. |
|
Jun 15, 2022
Former FDA DMEPA Director and Head of Brand Institute's Regulatory Division Updates the Company's Services Based on Recent FDA Safety Guidance Brand Institute, the global leader in pharmaceutical and healthcare related name development, is pleased to announce incorporation of the principles and recommendations from the finalized US Food and Drug Administration FDA guidance, Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors, into the company's label/labeling design and review services |
|
May 26, 2022
FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022. FDA approved Radicava ORS (edaravone) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS). |
|
May 23, 2022
Fujifilm's FIPAS™ Service Offers High-Tech Solution for Infrastructure Maintenance Brand Institute is proud to announce having worked with Fujifilm Corporation in developing the FIPAS™ brand name. FIPAS™ is a photo analysis service that utilizes cloud-based software to automatically identify deteriorations in concrete from photos and estimate their size. |
|
May 19, 2022
Hyundai Updates Award Winning Venue® SUV for 2022 Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received a 5-Year Cost to Own recognition award from Kelley Blue Book for a third consecutive year. |
|
May 04, 2022
FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022. |
|
Apr 18, 2022
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Apr 25, 2022
FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc. Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022. |
|
Apr 19, 2022
Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder & Principal of Urban Venture Group (UVG), to design the company's new corporate office located at the Ritz-Carlton Reserve Dorado Beach Resort |
|
Apr 18, 2022
FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
Mar 28, 2022
Oasmia announces completion of name change to Vivesto Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. |
|
Feb 22, 2022
Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test. |
|
Feb 3, 2022
Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school in Florida, Puerto Rico, that specializes in teaching baseball, academics, and the personal development of their students. |
|
Feb 1, 2022
FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency. |
|
Jan 24, 2022
Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson is a naming-industry veteran and 24-year employee of Brand Institute, Inc. |
2021 |
|
Aug 29, 2022
Brand Institute Partners on Brand Name Development for FDA Approved Hormonal Contraceptive Ring for the Prevention of Pregnancy Brand Institute is proud to announce its work with Mayne Pharma in developing the brand name HALOETTE®. |
|
Aug 23, 2022
Brand Institute to Moderate Round Table on Pharmaceutical Brand Naming Hosted by Harvard Business School Healthcare Alumni Association Brand Institute is pleased to announce that it will be moderating a Virtual Round Table (VRT) hosted by the Harvard Business School Healthcare Alumni Association (HBSHAA) titled: The Pursuit of a Global Pharmaceutical Brand Name. |
|
Dec 22, 2021
FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients. |
|
Dec 21, 2021
EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®. |
|
Dec 19, 2021
Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®. |
|
Dec 13, 2021
FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia). |
|
Dec 10, 2021
FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19 Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19. |
|
Dec 07, 2021 - Cision
MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19 Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection. |
|
Nov 24, 2021 - Cision
FDA Approves Takeda's Livtencity™ (maribavir), First Treatment Approved for Post-Transplant Cytomegalovirus (CMV) Infection Resistant to Other Drugs Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV. |
Oct 29, 2021 - ImaginAb
ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology. |
|
Sep 20, 2021 - Cision
Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty®, Spikevax® and Vaxzevria® for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively Brand Institute is proud to announce its role in naming all three COVID-19 vaccine brand names recently approved by Health Canada: Comirnaty® (Pfizer/BioNTech), Spikevax® (Moderna), and Vaxzevria® (AstraZeneca). |
|
Aug 25, 2021 - Cision
FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S. Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
|
Jul 22, 2021
Vaxzevria® Brand Naming Strategy and Logo Revealed Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to share the official logo and creative naming strategy for AstraZeneca's COVID-19 vaccine: Vaxzevria® (vax zev' ree ah). |
2020 |
|
Dec 28, 2020
Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
2022 |
|---|
|
Aug 15, 2022 Brand Institute's Vice President of Market Research and Commercial Strategy on the Importance of Market Research Panels in Brand Development Brand Institute's Vice President of Market Research and Commercial Strategy, Joe Bazerghi, who spearheaded the expansion of Brand Institute's market research panel of health care providers and patients across 180 countries, offers sage advice on the importance of market research panels in naming and brand development. |
|
Aug 10, 2022 Brand Institute's Head of Trademarks on the Impact of the US Trademark Modernization Act of 2020 (TMA) Brand Institute's Head of Trademarks, Rogelio Reyes, Esq., is pleased to offer a summary regarding the Trademark Modernization Act of 2020 (TMA), which took effect on December 18, 2021. |
|
Aug 08, 2022 Brand Institute Partners on Brand Name Development for FDA Approved Treatment to Help Retinal Disease Patients Maintain or Gain Vision Brand Institute is proud to announce its work with Coherus BioSciences in developing the brand name CIMERLI™ (ranibizumab-eqrn), under which the interchangeable biosimilar approved by the Food and Drug Administration (FDA) on August 2, 2022, will be marketed. |
|
Aug 03, 2022 Brand Institute President of Nonproprietary Naming Division Advises Clients on Guidance Set Forth by INN Regarding COVID-19 Variant Vaccines Brand Institute's President of its Nonproprietary Naming Division, Sophia Fuerst, M.S., M.B.A., is pleased to offer summary insights regarding recently implemented procedures for international nonproprietary names (INNs), specifically INNs for Variant COVID-19 Vaccine Active Substances. |
|
Jul 27, 2022 Brand Institute's Jerry Phillips on the Impact of the FDA's Proposed Rule to Modify the NDC and Barcode Regulations Brand Institute (BI) is pleased to share President of Regulatory Strategy Jerry Phillips' summary on the recent FDA proposal to modify its regulations to establish a uniform, 12-digit format for the National Drug Code (NDC) (21 CFR 207.33) that can accommodate longer NDCs once the FDA begins issuing 6-digit labeler codes. |
|
Jul 25, 2022 Brand Institute Welcomes Former Amgen Associate General Counsel and Executive Director Timothy J. Gaul as Vice President of Intellectual Property Strategy Brand Institute is pleased to announce the appointment of Timothy J. Gaul to the role of Vice President, Intellectual Property Strategy. |
|
Jul 21, 2022 Brand Institute's President of Canadian Regulatory Affairs Updates Brand Name Assessment Methodology Based on Health Canada Trends Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is pleased to announce new processes in its workflow. |
|
Jul 05, 2022 Brand Institute Partners on Brand Name Development for Treatment of Relapsed or Refractor Peripheral T-Cell Lymphoma Now Approved by Ministry of Health, Labour and Welfare (Japan) Brand Institute is proud to announce its work with Solasia Pharma K.K. ("Solasia") in developing the brand name DARVIAS®. |
|
Jun 27, 2022 Brand Institute SVP of Nonproprietary Naming Division Shares Naming Guidance on Evolving Nomenclature Schemes Set Forth by Regulatory Agencies (USAN and INN) Brand Institute's Senior Vice President of Regulatory Affairs for the company's Nonproprietary Naming Division, Sandra Van Laan, B.S., is pleased to share new guidance on monoclonal antibody naming, published by INN in November 2021. |
|
Jun 27, 2022 Brand Institute Partners on Brand Name Development for European Commission Authorized Vaccine for the Prevention of Hepatitis B Brand Institute is proud to announce its work with VBI Vaccines in developing the brand name PreHevbri™. |
|
Jun 23, 2022 Brand Institute Executive, a Former FDA Team Leader, Celebrates 15 Years with Company's Subsidiary, Drug Safety Institute Brand Institute, the global leader in pharmaceutical and healthcare-related name development, recently celebrated the 15-year anniversary of former FDA Team Leader, Dr. Nora Roselle, with Brand Institute/Drug Safety Institute. |
|
Jun 21, 2022 Brand Institute Partners on Brand Name Development for FDA Approved Treatment for Febrile Neutropenia in Cancer Patients Brand Institute is proud to announce having worked with Adello Biologics (acquired by Kashiv Biosciences in 2019) in developing the brand name FYLNETRA® (pegfilgrastim-pbbk), for an injection used to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. |
|
Jun 15, 2022 Former FDA DMEPA Director and Head of Brand Institute's Regulatory Division Updates the Company's Services Based on Recent FDA Safety Guidance Brand Institute, the global leader in pharmaceutical and healthcare related name development, is pleased to announce incorporation of the principles and recommendations from the finalized US Food and Drug Administration FDA guidance, Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors, into the company's label/labeling design and review services |
|
May 26, 2022 FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022. FDA approved Radicava ORS (edaravone) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS). |
|
May 23, 2022 Fujifilm's FIPAS™ Service Offers High-Tech Solution for Infrastructure Maintenance Brand Institute is proud to announce having worked with Fujifilm Corporation in developing the FIPAS™ brand name. FIPAS™ is a photo analysis service that utilizes cloud-based software to automatically identify deteriorations in concrete from photos and estimate their size. |
|
May 19, 2022 Hyundai Updates Award Winning Venue® SUV for 2022 Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received a 5-Year Cost to Own recognition award from Kelley Blue Book for a third consecutive year. |
|
May 04, 2022 FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022. |
|
Apr 18, 2022 FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Apr 25, 2022 FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc. Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022./span> |
|
Apr 19, 2022 Fernando González Díaz to Design Brand Institute's New Corporate Office in Puerto Rico As Brand Institute expands its operations in San Juan, Puerto Rico, it is proud to announce that it has enlisted Fernando González Díaz, Founder & Principal of Urban Venture Group (UVG), to design the company's new corporate office located at the Ritz-Carlton Reserve Dorado Beach Resort |
|
Apr 18, 2022 FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed. |
|
Mar 28, 2022 Oasmia announces completion of name change to Vivesto Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, announces that as of today, 28 March, its new name, Vivesto AB, has been registered with the Swedish Companies Registration Office. |
|
Feb 22, 2022 Maxim Biomedical's ClearDetect™ COVID-19 Antigen Home Test Receives Emergency Use Authorization (EUA) from the U.S. FDA Brand Institute is proud to announce its successful partnership with Maxim Biomedical (MaximBio) in naming their MaximBio ClearDetect™ COVID-19 Antigen Home Test. |
|
Feb 3, 2022 Carlos Beltrán Baseball Academy (CBBA) Partners with Global Naming Agency Brand Institute Brand Institute is proud to announce its support and enthusiastic patronage of the Carlos Beltrán Baseball Academy (CBBA), a prestigious high school in Florida, Puerto Rico, that specializes in teaching baseball, academics, and the personal development of their students. Its curriculum is singularly holistic, emphasizing both home runs and homework, pop flies and pop quizzes, batting averages and grade point averages—equally. |
|
Feb 1, 2022 FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their FDA-approved COVID-19 vaccine: SPIKEVAX®, the second COVID-19 vaccine to be fully approved by the regulatory agency. |
|
Jan 24, 2022 Brand Institute Appoints William (Bill) Johnson to Co-Chief Executive Officer & President Brand Institute is pleased to announce the appointment of William (Bill) Johnson to the role of Co-Chief Executive Officer and President. Mr. Johnson is a naming-industry veteran and 24-year employee of Brand Institute, Inc. |
2021 |
|
Dec 22, 2021 FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients. |
|
Dec 21, 2021 EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®. |
|
Dec 19, 2021 Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®. |
|
Dec 13, 2021 FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia). |
|
Dec 10, 2021 FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19 Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19. |
|
Dec 07, 2021 MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19 Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection. |
|
Nov 24, 2021 FDA Approves Takeda's Livtencity™ (maribavir), First Treatment Approved for Post-Transplant Cytomegalovirus (CMV) Infection Resistant to Other Drugs Brand Institute is proud to announce its successful partnership with Takeda Pharmaceuticals Company Limited in naming the first treatment approved by the US Food & Drug Administration (FDA) for adults and pediatric patients with post-transplant cytomegalovirus (CMV) infection that does not respond to available antiviral treatment for CMV. |
|
Oct 29, 2021 ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology ImaginAb Inc, a market-leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and radiopharmaceutical therapy (RPT), today announced it will be partnering with Miami-based branding agency, Brand Institute, on the development of a global brand name for ImaginAb’s CD8 ImmunoPET technology. |
|
Sep 20, 2021 Health Canada Approves COVID-19 Vaccine Brand Names Comirnaty®, Spikevax® and Vaxzevria® for Pfizer/BioNTech, Moderna and AstraZeneca, Respectively Brand Institute is proud to announce its role in naming all three COVID-19 vaccine brand names recently approved by Health Canada: Comirnaty® (Pfizer/BioNTech), Spikevax® (Moderna), and Vaxzevria® (AstraZeneca). |
|
Aug 25, 2021 FDA Approves COMIRNATY®, The First COVID-19 Vaccine Approved By The Agency And The First COVID-19 Vaccine Brand Name Approved In The U.S. Brand Institute is proud to announce its role in naming Pfizer and BioNTech's FDA-approved COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |
|
Jul 22, 2021 Vaxzevria® Brand Naming Strategy and Logo Revealed Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to share the official logo and creative naming strategy for AstraZeneca's COVID-19 vaccine: Vaxzevria® (vax zev' ree ah). |
2020 |
|
Dec 28, 2020 Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). |